A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
A REVIEW ON USE OF TOCILIZUMAB
FOR THE TREATMENT OF COVID-19
Dr.Elayakumar S.T Senior Resident1,
Dr. Anbumalar M Assistant Professor2
Meenakshi Academy of Higher Education and Research
anbumalar@mmchri.ac.in
Abstract
Although a viral infection begins in COVID-19, some patients have overly exuberant
inflammation, leading to acute pulmonary injury and a condition of adult respiratory
distress (ARDS). As IL-6 is a key role in the inflammatory response, in this single centre
observatory study in all Covid-19 patients with a proven SARS-CoV-2 fast-pacing infection
in order to escape ALI and ARDS we have assessed the effectiveness and protection of
tocilizumab (TCZ). In this single centre The rate of mortality in 104 patients treated for
COVID-19 was lower (5 · 8%). The percentage of patients treated with COVID-19 was 11%
lower than in untreated patients who had our level of treatment alone and a marginally
lower rate of mortality (6 percent ). The acute phase reagents, Ferritin, and liver protein
releases were quickly diminished by TCZ. Slowly, D-Dimer declined. Relevant safety issues
were not found. An early prescribing of IL6-R antagonists can be safe and successful for
avoidance, ICU admission and more complications in COVID-19 patients with imminent
hyperinflammatory reaction1.
Keywords: COVID-19, Tocilizumab, Pandemic, Treatment
BACKGROUND
The evidence indicates that the immediate and rapid release of various cytokines as a serious
immune reaction ("cytokine release syndrome" CRS) is present in sub-sets of extreme
COVID-19 patients, contributing to acute respirory distress syndrome (ARDS). This septic
storm will lead to life-threatening failure of a variety of organs. The CRS may be induced by
infections, trauma, or clinical intervention such as a chimeric antigen receptor (CAR)-T cell
injection, first described in previous outbreak procedures in patients with severe acute
respiratory Syndrome (SARS) or Middle East Respiratory syndrome (MERS-CoV), all
caused by corónaviruses. Immune response dysregulation was also recorded in COVID-192–5.
Interestingly, the extensive cytokine storm is played by IL-2, IL- 7, IL-10, IL-12, interferon
β, inflammatory macrophage protein 1-α, and tumour necrosis factor-α, while the excellent
cytokine seems to have IL-6. IL-6 is a pleiotropically activated cytokine. The defensive work
against the viruses repairing the tissue affected by this acute process and by immune
responses is carried out by mainly macrophages, fibroblasts and dendritic cells in response to
pathogen allocated molecular patterns (PAMPs) or molecular damage-associated patterns
(DAMPs). In most extreme COVID-19 cases the existence of CRS has been showed to be a
stimulating factor in granulocytes-colony-colony (G-CSF), interferon-α-inducible protein
5752European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
(IP10), monocyte chemoattractant protein (MCP1), macro-colonial inflammatory protein 1
alpha (MIP1A). In the end, IL-6 will reach vast amounts of inflammatory cytokines, causing
physical lung disability and death6–8.
The recombinant humanised anti-interleukin-6 (IL-6R) monoclonal antibody, Tocilizumab
(TCZ), has been found to be an alternative for use in this outbreak that prevents IL-6 from
binding to solutionble and membrane-bound IL-6R Based on methodologically weak, but
positive results of tocilizumab in the treatment of severe COVID-19 patients from
observational studies, case reports 9–11 and the experience of tocilizumab in inducing rapid
reversal of CAR T cell-induced CRS , several clinical trials are being conducted to assess the
efficacy and safety of tocilizumab in severe COVID-19 patients.
Tocilizumab for the treatment of COVID-19
The current COVID19 pandemic is a challenge to world health and health services that is
unparalleled. Older individuals with age-related illnesses that experience hyper-inflammatory
syndrome are the highest mortality rate. Here, we believed that the magnitude of COVID-19
may be associated with inflammation. Here the clinical response assessments for a one dose
intravenous injection of the anti-IL-6 receptor Tocilizumab (TCZ) in COVID-19 patients 12–
15
with multifocal interstitial pneumonia were evaluated by 30 serum samples from patients
registered in the Clinical trial NCT04315480.We have assessed a range of RNAs that regulate
inflammatory activity (i.e. miR-146a-5p, miR-21-5, and miR-126-3p) quantified by RT-PCR
and Droplet Digital PCR, in these serum samples as well as in 29 age- and gender-based
stable control subjects. Signified dysregulation by pro-inflammatory cytokines, a syndrome
termed cytokine storm, is present in a large proportion of hospitalised COVID-19 patients16–
18
. In COVID-19 patients, such hyperinflammatory reaction is consistent with severe
pneumonia and endothelial injury and microvascular dysfunction as well as with the lung and
multiorgan insufficiency. Consequently, the efficacy of anticytokine/cytokine receptor
antibodies for the treatment of COVID 19 patients is unsurprising to have been started in a
series of clinical studies One of such host-directed therapies is tocilizumab (TCZ), the
monoclonal interleukin-6 (IL-6) receptor antibody. However a major heterogeneity has been
documented in the clinical response of COVID-19 patients to TCZ therapy, possibly because
of the contribution of other considerations like age-related biological processes, gender,
genetic composition, seriousness of the disorder, timing, and immune activation. On the
above issue, recently we have indicated that unregulated COVID-19 associated
hyperinflammation can be promoted by age based pro-inflammatory status that is currently
referred to as inflammatory, particularly in ages. It is desperately important to channel this
useful armament to those patients that are more likely to gain from blood bio-markers that are
conceivablely related to systemic inflammatory disorders and/or inflammation and are
capable of predirecting the reaction to TCZ therapy. From this point of view, the evaluation
of microRNAs (miRNAs), including age associated and infectious diseases, has emerged like
a reliable instrument to determine the pharmacologic therapies in a range of human diseases.
Many recent research showed that a major cause of death in COVID-19 patients was the
Cytokine Freedom syndrome (CRS), of which IL-6 was an important component. Herold et
al. found the IL-6 level in patients with COVID-19 to predict respiratory failure (including 40
patients). The rise in IL-6 has been closely associated with mechanical ventilation criteria (p
5753European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
< 0.001). Furthermore, patients with highest IL-6 could easily predict respiratory
insufficiency (pEuropean Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
of associated serious thromboembolic disease (COVID-19) but also to the growth of lung and
subsequent fibrosis. However, for reasons that remain unclear, only a subgroup of patients
with COVID-19 experience genius respiratory failure. An constant problem is the optimal
control of these situations. However, elevated amounts of other routine laboratory
parameters, including C-RP, lactate dehydrogenase, and ferritin, D-dimer along with
lymphocytopenia, were reported in COVID-19 cases of rapidly growing respiratory disease.
IL-6 is a key inflammatory mediator when developing COVID-19 related hyperinflammation.
A recombinant humanised monoclonal antibody, Tocilizumab ( TCZ), was proposed to
alleviate the related cytokine hurricane, COVID-19 for the treatment of extreme COVID-19,
but with differing clinical outcomes, against both soluble and membrane-bound IL-6
receptors. We will present the clinical characteristics of COVID-19 patients who have
undergone therapy with TCZ in this one-center retrospective review, and explain their course
and outcomes.
REFERENCES:
1. Widysanto A, Kurniawan A, Lugito NPH, et al. Experience of using tocilizumab for
treatment in Indonesian patients with severe COVID-19. Cytokine. 2021;138.
doi:10.1016/j.cyto.2020.155393
2. Corominas H, Castellví I, Pomar V, et al. Effectiveness and safety of intravenous
tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-
6 observational cohort. Clin Immunol. 2021;223. doi:10.1016/j.clim.2020.108631
3. Sabbatinelli J, Giuliani A, Matacchione G, et al. Decreased serum levels of the
inflammaging marker miR-146a are associated with non-clinical response to
tocilizumab in COVID-19 patients. Mech Ageing Dev. 2021;193.
doi:10.1016/j.mad.2020.111413
4. Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the
treatment of COVID-19: A multicenter trial in a small sample size. Biomed
Pharmacother. 2021;133. doi:10.1016/j.biopha.2020.110825
5. Muccioli L, Pensato U, Cani I, et al. COVID-19-related encephalopathy presenting
with aphasia resolving following tocilizumab treatment. J Neuroimmunol. 2020;349.
doi:10.1016/j.jneuroim.2020.577400
6. Huang E, Jordan SC. Tocilizumab for Covid-19 - The ongoing search for effective
therapies. N Engl J Med. 2020;383(24):2387-2388. doi:10.1056/NEJMe2032071
7. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients
hospitalized with covid-19. N Engl J Med. 2020;383(24):2333-2344.
doi:10.1056/NEJMoa2028836
8. Wang Y, Mao Q, Zhou X. Does tocilizumab have a magical therapeutic effect on
COVID-19 patients without obvious adverse reactions? Proc Natl Acad Sci U S A.
2020;117(49):30896-30897. doi:10.1073/pnas.2009961117
9. Vu CA, DeRonde KJ, Vega AD, et al. Effects of Tocilizumab in COVID-19 patients: a
cohort study. BMC Infect Dis. 2020;20(1). doi:10.1186/s12879-020-05701-4
10. Xu X, Han M, Li T, et al. Tocilizumab treatment in COVID-19 patients needs the
5755European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
assessment of the disease severity and timely intervention. Proc Natl Acad Sci U S A.
2020;117(48):30027-30028. doi:10.1073/pnas.2011616117
11. Yang C, Liu E, Liu M. Safety concerns regarding concomitant use of tocilizumab and
glucocorticoids in COVID-19 patients. Proc Natl Acad Sci U S A.
2020;117(48):30025-30026. doi:10.1073/pnas.2009253117
12. Salvati L, Occhipinti M, Gori L, et al. Pulmonary vascular improvement in severe
COVID-19 patients treated with tocilizumab. Immunol Lett. 2020;228:122-128.
doi:10.1016/j.imlet.2020.10.009
13. Rubio-Rivas M, Ronda M, Padulles A, et al. Beneficial effect of corticosteroids in
preventing mortality in patients receiving tocilizumab to treat severe COVID-19
illness. Int J Infect Dis. 2020;101:290-297. doi:10.1016/j.ijid.2020.09.1486
14. de Cáceres C, Martínez R, Bachiller P, Marín L, García JM. The effect of tocilizumab
on cytokine release syndrome in COVID-19 patients. Pharmacol Reports.
2020;72(6):1529-1537. doi:10.1007/s43440-020-00186-z
15. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on
mortality in severe COVID-19. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-76187-y
16. Kaminski MA, Sunny S, Balabayova K, et al. Tocilizumab therapy for COVID-19: A
comparison of subcutaneous and intravenous therapies. Int J Infect Dis. 2020;101:59-
64. doi:10.1016/j.ijid.2020.09.1447
17. Malekzadeh R, Abedini A, Mohsenpour B, et al. Subcutaneous tocilizumab in adults
with severe and critical COVID-19: A prospective open-label uncontrolled multicenter
trial. Int Immunopharmacol. 2020;89. doi:10.1016/j.intimp.2020.107102
18. Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic
lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case
report. J Med Case Rep. 2020;14(1). doi:10.1186/s13256-020-02503-9
19. Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for
treatment patients with COVID-19: Recommended medication for novel disease. Int
Immunopharmacol. 2020;89. doi:10.1016/j.intimp.2020.107018
20. Guaraldi G, Milic J, Cozzi-Lepri A, Pea F, Mussini C. Tocilizumab in COVID-19:
finding the optimal route and dose – Authors’ reply. Lancet Rheumatol.
2020;2(12):e739-e740. doi:10.1016/S2665-9913(20)30333-7
21. Jain S, Jain S, Sharma SK. Tocilizumab in COVID-19: finding the optimal route and
dose. Lancet Rheumatol. 2020;2(12):e738-e739. doi:10.1016/S2665-9913(20)30334-9
22. Bernardo L, Del Sesto S, Giordano L, et al. Severe prolonged neutropenia following
administration of tocilizumab in a patient affected by COVID-19: a case report and
brief review of the literature. Drugs Ther Perspect. 2020;36(12):568-572.
doi:10.1007/s40267-020-00777-z
23. Mantero V, Rigamonti A, Basilico P, Crespi M, Balgera R, Salmaggi A. Mild COVID-
19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6
protective role? J Neurol. 2020;267(12):3465-3466. doi:10.1007/s00415-020-10039-7
24. Wise J. Covid-19: Critically ill patients treated with arthritis drug tocilizumab show
improved outcomes, researchers report. BMJ. 2020;371:m4530.
5756European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020
doi:10.1136/bmj.m4530
25. Nakamura H, Miyagi K, Otsuki M, et al. Acute hypertriglyceridaemia caused by
tocilizumab in a patient with severe COVID-19. Intern Med. 2020;59(22):2945-2949.
doi:10.2169/internalmedicine.5244-20
26. Jiménez-Brítez G, Ruiz P, Soler X. Tocilizumab plus glucocorticoids in severe and
critically COVID-19 patients. A single center experience [Tocilizumab más
glucocorticoides para tratar pacientes graves y en situación crítica infectados por
COVID-19. Experiencia de un centro]. Med Clin (Barc). 2020;155(9):410-411.
doi:10.1016/j.medcli.2020.07.001
27. Kaye AG, Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe
COVID-19 mortality: a systematic review. PeerJ. 2020;8. doi:10.7717/peerj.10322
28. Berardicurti O, Ruscitti P, Ursini F, et al. Mortality in tocilizumab-treated patients with
COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol.
2020;38(6):1247-1254. https://www.scopus.com/inward/record.uri?eid=2-s2.0-
85097310697&partnerID=40&md5=d8fecf71b30d28052df7f9427f1e07a7.
29. Gergi M, Cushman M, Littenberg B, Budd RC. Thromboinflammation response to
tocilizumab in COVID-19. Res Pract Thromb Haemost. 2020;4(8):1262-1268.
doi:10.1002/rth2.12436
30. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, et al. Clinical
characteristics and outcomes among hospitalized adults with severe COVID-19
admitted to a tertiary medical center and receiving antiviral, antimalarials,
glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A
retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020;28.
doi:10.1016/j.eclinm.2020.100591
31. Algazaq J, Hiraldo-Infante C, Miskovsky J. Tocilizumab treatment in COVID-19-
induced cytokine release syndrome. Infect Dis Clin Pract. 2020;28(6):e76-e78.
doi:10.1097/IPC.0000000000000940
32. Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM. Tocilizumab and
Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). Obstet
Gynecol. 2020;136(5):1025-1029. doi:10.1097/AOG.0000000000004050
5757You can also read
